3 FDA-Cleared Blood Tests Narrow Dementia Diagnosis Gap
Three FDA-cleared blood-based biomarkers for Alzheimer’s disease have narrowed the gap between dementia science and clinical practice, according to [psychiatrictimes.com] reported. These tests, introduced over a little more than a year, aim to replace imprecise diagnoses like “dementia” with specific classifications, enabling targeted therapies. George Grossberg, the Henry and Amelia Nasrallah Professor in Geriatric Psychiatry at Saint Louis University School of Medicine, emphasized that “once you know what you’re dealing with more specifically, you can target more appropriate therapy.”
Biomarkers Offer Precision, But Not a Standalone Diagnosis
MedicalNewsToday reported that two new FDA-cleared tests—C2N Diagnostics’ PrecivityAD2 and Roche’s Elecsys pTau217—measure amyloid-beta and tau proteins to identify brain changes linked to Alzheimer’s. PrecivityAD2, approved for adults as young as 40, combines amyloid and tau biomarkers into an algorithm called the amyloid probability score 2 (APS2). However, neither test should be used as a standalone diagnostic tool, the outlet noted.
“A positive biomarker result at that age can have major implications for work, family, and emotional well-being,” warned a researcher cited in MedicalNewsToday. The tests require interpretation alongside symptoms, medical history, and clinical findings, as highlighted by [psychiatrictimes.com].
Challenges in Biomarker Development
Biomarkers for neurological diseases remain complex, with [labiotech.eu] reporting that collecting cerebrospinal fluid (CSF) samples—traditionally used to detect alpha-synuclein in Parkinson’s—remains challenging due to low analyte concentrations. Antti Vuolanto, CEO of Herantis Pharma, noted that “highly sensitive methods” are critical for fluid-based biomarkers, a hurdle that has slowed progress in the field.
Despite these challenges, blood tests are gaining traction. [labiotech.eu] noted that imaging tests like PET scans, while effective, are costly and often secondary to clinical evaluations. Blood-based biomarkers offer a less invasive alternative, though their accuracy in younger populations remains under scrutiny.
High P-Tau217 Levels Increase Cognitive Impairment Risk
Research published in [myjournalcourier.com] found that older adults with high p-tau217 levels had a 38% risk of developing cognitive impairment within five years. However, the outlet stressed that “a positive test result is just a risk factor, not a guarantee.” Experts like Nicholas Ashton of Banner Health advised against testing asymptomatic individuals, stating, “The worried well should not be getting those tests outside of a research study.”
Studies also show lifestyle interventions can delay dementia onset. [myjournalcourier.com] cited a large study where individuals without high blood pressure, diabetes, or smoking lived nearly 13 years longer without dementia. Aggressive treatment of risk factors, such as high blood pressure, was highlighted as a critical step for brain health.
Future of Alzheimer’s Diagnosis
The European Medical Journal’s expert panel emphasized that early diagnosis is crucial for effective treatment. Blood-based biomarkers, they noted, could streamline referral pathways and improve outcomes. However, [psychiatrictimes.com] reported that clinicians must balance optimism with caution, as the “performance estimates from studies may not apply identically to younger patients.”
The FDA-cleared PrecivityAD2 test is expected to become available later in 2026, according to MedicalNewsToday. Meanwhile, the broader adoption of these tests depends on clinician training and integration into standard care protocols.
Blood Tests Require Clinical Data for Interpretation
Alzheimer’s blood tests can detect amyloid-beta and tau proteins, but they require interpretation alongside clinical data. For example, C2N Diagnostics’ PrecivityAD2 combines biomarker ratios into an algorithm, yet it’s not a standalone diagnostic tool.
Pro Tip
Patients considering Alzheimer’s biomarker tests should consult their doctor to determine if testing is appropriate based on symptoms and risk factors. Lifestyle changes, such as managing blood pressure and avoiding smoking, remain key to reducing dementia risk.
How Many FDA-Cleared Alzheimer’s Blood Tests Are Available?
How many FDA-cleared Alzheimer’s blood tests are available?
Four FDA-cleared blood tests exist for Alzheimer’s, according to [medicalnewstoday.com].
Can these tests diagnose Alzheimer’s on their own?
No. [medicalnewstoday.com] states that results must be interpreted alongside symptoms, medical history, and other clinical findings. They are not standalone diagnostic tools.
When will the newest test be available?
C2N Diagnostics’ PrecivityAD2 is expected to become available later in 2026, as reported by [medicalnewstoday.com].